Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our opinions or reviews. Learn how we make money.
Alexion Pharmaceuticals, Inc is a biotechnology business based in the US. Alexion Pharmaceuticals shares (ALXN) are listed on the NASDAQ and all prices are listed in US Dollars. Alexion Pharmaceuticals employs 3,082 staff and has a trailing 12-month revenue of around USD$5.5 billion.
Since the stock market crash in March caused by coronavirus, Alexion Pharmaceuticals's share price has had significant positive movement.
Its last market close was USD$113.57, which is 9.18% up on its pre-crash value of USD$103.14 and 56.28% up on the lowest point reached during the March crash when the shares fell as low as USD$72.67.
If you had bought USD$1,000 worth of Alexion Pharmaceuticals shares at the start of February 2020, those shares would have been worth USD$804.81 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,126.61.
|Latest market close||USD$113.57|
|52-week range||USD$72.67 - USD$121.5|
|50-day moving average||USD$105.2994|
|200-day moving average||USD$102.8799|
|Wall St. target price||USD$141.32|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$3.808|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-09-07)||N/A|
|1 month (2020-08-14)||N/A|
|3 months (2020-06-18)||-2.36%|
|6 months (2020-03-14)||N/A|
|1 year (2019-09-14)||N/A|
|2 years (2018-09-14)||N/A|
|3 years (2017-09-14)||N/A|
|5 years (2015-09-14)||N/A|
Valuing Alexion Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Alexion Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Alexion Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 28x. In other words, Alexion Pharmaceuticals shares trade at around 28x recent earnings.
That's comparable to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29).
Alexion Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.6965. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Alexion Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Alexion Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$2.9 billion.
The EBITDA is a measure of a Alexion Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$5.5 billion|
|Operating margin TTM||46.4%|
|Gross profit TTM||USD$4.6 billion|
|Return on assets TTM||10.27%|
|Return on equity TTM||8.19%|
|Market capitalisation||USD$24.1 billion|
TTM: trailing 12 months
There are currently 4.8 million Alexion Pharmaceuticals shares held short by investors – that's known as Alexion Pharmaceuticals's "short interest". This figure is 8.6% up from 4.4 million last month.
There are a few different ways that this level of interest in shorting Alexion Pharmaceuticals shares can be evaluated.
Alexion Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Alexion Pharmaceuticals shares currently shorted divided by the average quantity of Alexion Pharmaceuticals shares traded daily (recently around 1.6 million). Alexion Pharmaceuticals's SIR currently stands at 3. In other words for every 100,000 Alexion Pharmaceuticals shares traded daily on the market, roughly 3000 shares are currently held short.
However Alexion Pharmaceuticals's short interest can also be evaluated against the total number of Alexion Pharmaceuticals shares, or, against the total number of tradable Alexion Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Alexion Pharmaceuticals's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Alexion Pharmaceuticals shares in existence, roughly 20 shares are currently held short) or 0.023% of the tradable shares (for every 100,000 tradable Alexion Pharmaceuticals shares, roughly 23 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Alexion Pharmaceuticals.
Find out more about how you can short Alexion Pharmaceuticals stock.
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Alexion Pharmaceuticals.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 32.02
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Alexion Pharmaceuticals's overall score of 32.02 (as at 08/01/2020) is nothing to write home about – landing it in it in the 42nd percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Alexion Pharmaceuticals is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 8.12/100
Alexion Pharmaceuticals's environmental score of 8.12 puts it squarely in the 9th percentile of companies rated in the same sector. This could suggest that Alexion Pharmaceuticals is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 25.12/100
Alexion Pharmaceuticals's social score of 25.12 puts it squarely in the 9th percentile of companies rated in the same sector. This could suggest that Alexion Pharmaceuticals is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 11.78/100
Alexion Pharmaceuticals's governance score puts it squarely in the 9th percentile of companies rated in the same sector. That could suggest that Alexion Pharmaceuticals is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Alexion Pharmaceuticals scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Alexion Pharmaceuticals has, for the most part, managed to keep its nose clean.
|Total ESG score||32.02|
|Total ESG percentile||41.58|
|Environmental score percentile||9|
|Social score percentile||9|
|Governance score percentile||9|
|Level of controversy||2|
We're not expecting Alexion Pharmaceuticals to pay a dividend over the next 12 months.
Alexion Pharmaceuticals's shares were split on a 2:1 basis on 23 May 2011. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Alexion Pharmaceuticals shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Alexion Pharmaceuticals shares which in turn could have impacted Alexion Pharmaceuticals's share price.
Over the last 12 months, Alexion Pharmaceuticals's shares have ranged in value from as little as $72.67 up to $121.5. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Alexion Pharmaceuticals's is 1.3952. This would suggest that Alexion Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS (eculizumab), a monoclonal antibody for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG and NMOSD; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1810 (Subcutaneous) that is in Phase I clinical trial for renal diseases; and ALXN1720 (Subcutaneous), which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 (WTX101) that is in Phase III clinical trials for the treatment of Wilson disease; and ALXN1830 and ABY-039, which are in Phase I clinical trials for neonatal Fc receptor. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; collaboration with Dicerna Pharmaceuticals, Inc. and Zealand Pharma A/S; strategic agreement with Caelum Biosciences, Inc.; agreement with Stealth BioTherapeutics Corp.; and a partnership with Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.